Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779780 | 0.82 | BACE1 (0.52) | CNR2BACE1ALOX5 | |
| SCHEMBL16480410 | 0.79 | CASP1 (0.48) | CNR2CNR1BACE1 | |
| SCHEMBL9893013 | 0.78 | KDM4E (0.50) | CNR2CNR1BACE1 | |
| SCHEMBL9891924 | 0.77 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL9893088 | 0.74 | PFKFB2 (0.46) | CNR2CNR1BACE1ALOX5 | |
| SCHEMBL30497309 | 0.72 | BRD4 (0.52) | CNR2CNR1 | |
| SCHEMBL9892143 | 0.72 | CNR2 (0.60) | CNR2CNR1ALOX5 | |
| SCHEMBL2579492 | 0.71 | CNR2 (0.47) | CNR2CNR1BACE1ALOX5 | |
| SCHEMBL9892389 | 0.71 | CNR2 (0.48) | CNR2CNR1BACE1ALOX5 | |
| SCHEMBL28425754 | 0.68 | HDAC3 (0.48) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885BACE1 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.